블로그
-
교류 회로 이론에서 배우는 것들
교류에서는 위상(Phase)의 개념을 잘 알아야 합니다. 순수 저항에서는 전압과 전류의 위상차(Phase difference)가 0(zero) 즉, 동상(In-phase)이지만 인덕터와 커패시터에서는 전.......
blog.naver.com · 2026.02.19
-
MRI로 항암치료 ‘횟수 줄이기’ 가능할까? HER2+ 유방암 TRAIN-3 연구가 던진 질문
(TRAIN-3): 다기관, 단일군, 2상 임상 연구의 주요 결과 MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2
blog.naver.com · 2026.04.10
-
모더나 - AACR 2026 암 학회 발표 주제 (4월 20일)
First-Line mRNA-4359 plus pembrolizumab (pembro) in locally advanced or metastatic melanoma: Results from the phase 1/2 mRNA-4359-P101 study First-Line (1차 치료): 전에 이 병으로 항암치료를 받은 적이 없는 '신규 환자'를 뜻함 mRNA-
blog.naver.com · 2026.04.04
-
모더나 - AACR 2026 암 학회 발표 주제 (4월 20일)
First-Line mRNA-4359 plus pembrolizumab (pembro) in locally advanced or metastatic melanoma: Results from the phase 1/2 mRNA-4359-P101 study First-Line (1차 치료): 전에 이 병으로 항암치료를 받은 적이 없는 '신규 환자'를 뜻함 mRNA-
blog.naver.com · 2026.04.04
-
[77호: Case Study] 국립한밭대학교 MPSE 연구실 : 멀티스케일 공정 해석으로 산업 난제를 해결하다
세부적으로는 미세 입자의 거동을 예측하는 MP-PIC-PBE(Multi-Phase Particle-In-Cell Coupled with Population Balance Equation
blog.naver.com · 2026.03.27
-
Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment
supported by statistically significant and clinically meaningful functional cure rates demonstrated in pivotal phase III B-Well trials Nearly 1 million people in Japan live with chronic hepatitis B1, a leading
blog.naver.com · 2026.02.27
-
Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer
Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer In the phase III DESTINY-Breast09 trial, first-line treatment with the antibody-drug conjugate fam-trastuzumab
blog.naver.com · 2025.06.27
-
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or ...
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Responses to endocrine monotherapy in advanced endometrial cancer are suboptimal, perhaps due to genomic
blog.naver.com · 2025.06.04
-
A phase 1b/2, open-label study of adrixetinib (Q702) in combination with intravenous pembrolizumab
The safety profile, pharmacokinetics (PK) and efficacy data for Q702 in combination with pembrolizumab Methods: QRNT-008 (NCT05438420) is an ongoing Phase 1b/2 multicenter, open-label, dose escalation and
blog.naver.com · 2025.06.03
-
릴리 경구GLP1제제, Orforglipron 3상 연구 발표
Phase 3 ATTAIN-1 trial of orforglipron (oral GLP-1 agonist): 릴리에서 개발한 경구용 non-peptide 약제인 올포글리프론 3상 임상시험 loss at 72 weeks with highest dose vs. −2.1% with placebo >50% of patients hit ≥10% weight loss 1 in
blog.naver.com · 2025.09.18
